Xladcort Tablet contains Deflazacort 6 mg, a corticosteroid with potent anti-inflammatory and immunosuppressive properties. It is primarily indicated for the management of various inflammatory and autoimmune conditions, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, polymyositis, and certain allergic disorders. Deflazacort exerts its therapeutic effects by modulating the immune response and inhibiting the release of pro-inflammatory mediators, thereby reducing inflammation and tissue damage. The 6 mg dosage offers an effective balance between efficacy and safety, minimizing potential corticosteroid-related adverse effects. Xladcort is also utilized in the treatment of Duchenne muscular dystrophy to improve muscle strength and function. Administration should be under strict medical supervision with dosage tailored to the severity of the condition and patient response. Common side effects may include gastrointestinal discomfort, hyperglycemia, increased susceptibility to infections, and mood alterations. Long-term use requires monitoring for potential complications such as osteoporosis, adrenal suppression, and growth retardation in pediatric patients. Abrupt discontinuation is discouraged to prevent adrenal insufficiency. Patients should inform their healthcare provider of any concurrent medications or comorbidities to avoid drug interactions. Xladcort Tablet is a valuable therapeutic agent in the management of inflammatory and autoimmune disorders when used judiciously.